Altria Group, Inc. (MO) navigates a critical inflection point in its long corporate history, managing a deeply profitable but structurally declining cigarette business while simultaneously executing a strategic pivot toward smoke-free products that will define its next chapter. This Form 10-K/A, an amendment to Altria's Annual Report on Form 10-K, primarily serves to incorporate the audited financial statements of its significant equity method investee, Anheuser-Busch InBev SA/NV (ABI) [Item 15 - Exhibits, ¶1], offering a window into the company's broader capital allocation strategy, the regulatory forces shaping its competitive landscape, the performance dynamics of its product portfolio, and the financial metrics that underpin its investment case. What follows is an integrated examination of these dimensions, drawing together the key themes from Altria's filing to present a cohesive picture of where the company stands and where it is headed.

I. Strategic Framework and Capital Allocation

Altria Group, Inc.'s corporate strategy rests on a dual foundation: maximizing cash generation from its core tobacco operations while deploying that capital into strategic investments and the development of a smoke-free product portfolio. The company's most prominent strategic investment is its significant equity stake in Anheuser-Busch InBev SA/NV (ABI), the global brewing giant. Altria's consolidated financial statements incorporate the financial results of ABI through the equity method of accounting, and this amendment filing specifically incorporates by reference ABI's audited consolidated financial statements as of December 31, 2025 and 2024, and for the years ended December 31, 2025, 2024, and 2023 [Item 15 - Exhibits, ¶1]. These financial statements, which appear on pages F-1 through F-85 in Exhibit 99.3, were audited by PwC Bedrijfsrevisoren BV / Reviseurs d'Entreprises SRL (PCAOB ID: 1350), an independent registered public accounting firm based in Diegem, Belgium [Item 15 - Exhibits, ¶1]. The inclusion of ABI's audited financials is significant given the material impact of ABI's earnings on Altria's consolidated results and represents a key component of Altria's broader strategy to diversify beyond its core tobacco operations into adjacent consumer packaged goods categories.

Altria's capital allocation priorities are evidenced by the structure and certifications contained within this filing. The company filed certifications from its Chief Executive Officer and Chief Financial Officer under Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 [Item 15 - Exhibits, Table 1], reflecting management's commitment to robust financial controls and transparent reporting — critical elements for maintaining the investor confidence that supports Altria's long-standing capital return programs, including its industry-leading dividend and share repurchase initiatives. The amendment was executed on behalf of the company by Heather A. Newman, Executive Vice President and Chief Financial Officer, who serves as the principal financial officer responsible for overseeing Altria's financial strategy and capital allocation decisions [Item 15 - Exhibits, Table 2]. This governance framework reinforces the discipline with which Altria approaches the balance between returning capital to shareholders and investing in the transformative initiatives required to reposition the company for a post-combustible future.

The ABI investment itself reflects Altria's approach to managing regulatory and portfolio risk. By maintaining a substantial ownership position in a global brewing company with operations spanning less-regulated consumer categories across international markets, Altria gains exposure to revenue streams and growth dynamics that differ meaningfully from those of its domestic tobacco business. The independent audit of ABI's financial statements by an international accounting firm underscores the due diligence and oversight applied across Altria's diversified investment portfolio, and the incorporation by reference of ABI's consolidated financial statements from its Form 20-F filing demonstrates the company's adherence to SEC disclosure requirements regarding significant equity method investments [Item 15 - Exhibits, Table 1].

II. Segment Performance and Product Portfolio

Altria's business is organized into two primary operating segments — smokeable products and oral tobacco products — each subject to distinct regulatory, competitive, and consumer demand dynamics. While this amendment filing does not restate Altria's full operational segment disclosures, the company's consolidated financial statements and management's discussion of segment performance are incorporated by reference to the original 10-K filing, with additional ABI financial data included in this amendment [Item 15 - Exhibits, Table 1].

The smokeable products segment encompasses cigarettes manufactured under the Marlboro brand — Altria's flagship premium offering and one of the most valuable consumer brands in the world — along with other cigarette brands and machine-made cigars. Marlboro has maintained significant market share leadership within the domestic cigarette category, supported by decades of brand equity, sustained promotional investments, and ongoing product innovation. However, this segment has faced persistent and structurally driven volume declines stemming from secular trends including heightened health awareness among consumers, escalating regulatory restrictions on marketing and product formulation, rising federal and state excise taxes that increase the price gap between legal products and illicit alternatives, and the gradual migration of adult consumers toward reduced-risk nicotine alternatives. The smokeable products segment has historically contributed the substantial majority of Altria's net revenues and operating income, making the management of these volume declines through pricing power and cost discipline a central financial imperative.

The oral tobacco segment includes moist smokeless tobacco products under the Copenhagen and Skoal brands — both market leaders in their category — along with snus and modern oral nicotine products such as the on! brand. This segment has similarly contended with category volume pressure while preserving leading market positions and demonstrating notable pricing power. The oral tobacco segment contributes an important and growing share of Altria's profits, though it remains smaller than the smokeable products segment in absolute revenue contribution.

In recent years, Altria has intensified its focus on innovative and reduced-risk products to address evolving consumer preferences and to position the company for a future in which combustible tobacco plays a diminishing role. The company's smoke-free product portfolio includes NJOY Ace (e-vapor), a device-based vaping platform acquired to compete in the rapidly growing e-cigarette category; on!, a modern oral nicotine pouch product positioned to compete against a wave of new entrants in the nicotine pouch space; and heated tobacco offerings that represent Altria's entry into the heat-not-burn category. These innovative products represent a strategic priority to diversify revenue streams and participate actively in the industry's transition toward potentially less harmful products. Altria continues to evaluate regulatory pathways and strategic partnership arrangements — including its relationship with Philip Morris International regarding heated tobacco commercialization rights in the United States — as it works to build scale and consumer acceptance in smoke-free categories.

The signature on this filing by Heather A. Newman confirms the company's certification of the financial information presented [Item 15 - Exhibits, Table 2], including the ABI financial statements contained within Exhibit 99.3 that are incorporated by reference.

III. Financial Performance and Key Metrics

The financial performance and key metrics of Altria Group, Inc. must be understood within the context of this particular filing — a 10-K/A amendment that serves to incorporate certain financial information by reference rather than restating Altria's standalone financial results in full. Under Item 15, the ABI consolidated financial statements as of December 31, 2025 and 2024, and for the years ended December 31, 2025, 2024, and 2023, are incorporated by reference from ABI's Annual Report on Form 20-F for the year ended December 31, 2025 [Item 15 - Exhibits, ¶1]. These financial statements, appearing on pages F-1 through F-85 in Exhibit 99.3, were audited by PwC Bedrijfsrevisoren BV [Item 15 - Exhibits, ¶1]. The inclusion of ABI's audited financials is material to Altria's consolidated financial reporting because under the equity method of accounting, Altria recognizes its proportionate share of ABI's net earnings as a component of its own earnings — meaning that ABI's financial performance directly impacts Altria's reported net income and earnings per share.

In connection with this amendment, Altria filed several required certifications and consents beyond the ABI financial statements themselves. These include the consent of PwC Bedrijfsrevisoren BV as the independent registered public accounting firm for ABI, the aforementioned certifications from Altria's Chief Executive Officer and Chief Financial Officer pursuant to Section 302 and Section 906 of the Sarbanes-Oxley Act of 2002, and the ABI financial statements as Exhibit 99.3 [Item 15 - Exhibits, Table 1].

It is important to note that Altria's standalone financial performance metrics — including total net revenue, adjusted diluted earnings per share, operating income, segment profitability, and related margin analysis — are disclosures typically found in the original Form 10-K's Management's Discussion and Analysis section (Item 7) and its audited financial statements (Item 8), rather than in this amendment. The original 10-K filing would have contained Altria's detailed segment results for its smokeable products and oral tobacco products segments, including net revenue trends, cost of sales, marketing and administrative expenses, and the impact of special items such as restructuring charges, asset impairments, or gains on strategic investments. Investors relying on this amendment filing should consult the original 10-K for Altria's complete standalone financial picture. The amendment filing reviewed here focuses specifically on incorporating the ABI financial statements required under Altria's disclosure obligations related to its significant equity method investment [Item 15 - Exhibits, ¶1].

IV. Regulatory Environment and Legal Oversight

As a major domestic tobacco company, Altria operates within one of the most heavily regulated business environments in the United States. The company's regulatory landscape is shaped principally by the Food and Drug Administration (FDA), which exercises comprehensive authority over tobacco products including cigarettes, smokeless tobacco, and e-vapor products under the Family Smoking Prevention and Tobacco Control Act. The FDA's regulatory purview encompasses product standards (including potential nicotine reduction mandates), premarket review of new tobacco products through the Premarket Tobacco Product Application (PMTA) and Substantial Equivalence pathways, marketing authorization determinations, and enforcement actions against unauthorized products. Each of these regulatory dimensions carries material implications for Altria's product portfolio, competitive positioning, and financial outlook.

The ABI investment, while primarily a financial strategy, also has a regulatory dimension. By maintaining exposure to less-regulated consumer categories through its investment in the global brewing industry, Altria gains a degree of diversification against the concentrated regulatory risk inherent in the domestic tobacco market. The filing notes the involvement of PwC Bedrijfsrevisoren BV, an independent registered public accounting firm based in Diegem, Belgium, which audited the ABI financial statements — underscoring the international dimension of Altria's regulatory and compliance obligations [Item 15 - Exhibits, ¶1].

Altria's approach to managing litigation and regulatory risk is further demonstrated through its rigorous financial reporting and compliance frameworks. The engagement of independent auditors and the filing of detailed certifications under the Sarbanes-Oxley Act reflect the company's commitment to transparency and internal control discipline. These controls are critical not only for satisfying SEC disclosure requirements but also for supporting Altria's capital allocation strategy, including its dividend and share repurchase programs, which depend on sustained investor confidence in the reliability of the company's financial reporting [Item 15 - Exhibits, Table 1]. The certifications filed under Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 represent management's formal attestation to the accuracy and completeness of the company's financial disclosures and the effectiveness of its internal controls over financial reporting [Item 15 - Exhibits, Table 1].

V. Outlook and Forward Guidance

Altria Group, Inc.'s outlook and forward guidance are shaped by the company's position at the intersection of a declining domestic cigarette industry and an ambitious strategic pivot toward smoke-free products. While the specific adjusted diluted EPS guidance and long-term growth targets for the current fiscal year are not detailed in this 10-K amendment filing — which, as discussed, primarily serves to incorporate ABI financial statements by reference [Item 15 - Exhibits, ¶1] — management's forward-looking perspective can be understood through the company's overall business strategy and the industry dynamics that influence its financial trajectory.

The domestic cigarette industry has experienced long-term and structurally driven volume declines that show no signs of abating. Management has historically guided for industry cigarette volume declines in the range of 4% to 6% annually, reflecting ongoing shifts in consumer behavior, rising health consciousness, escalating excise taxes at both the state and federal levels, expanding regulatory restrictions on marketing and product formulation, and the growing availability and awareness of nicotine alternatives including e-vapor products, nicotine pouches, and heated tobacco. Altria's smokeable products segment, anchored by the Marlboro brand, remains the primary driver of revenue and operating income, but the segment must contend with these ongoing headwinds while deploying pricing power and cost discipline to sustain profitability on a shrinking volume base.

Key assumptions underlying Altria's outlook include management's ability to manage the company's cost structure effectively, deploy pricing power across its premium brand portfolio without accelerating volume loss beyond secular trends, and execute on share repurchase programs to support adjusted diluted EPS growth despite declining cigarette volumes. Risks that could materially affect the outlook include: increased state and federal excise taxes that could widen the price gap with illicit products; FDA regulatory actions regarding nicotine levels, flavor restrictions, or marketing authorizations that could disrupt current product portfolios; the potential for continued illicit market growth in categories such as e-vapor and nicotine pouches; adverse litigation outcomes particularly related to ongoing tobacco-related lawsuits; and the pace of adult consumer adoption of smoke-free alternatives, which will determine the success and timing of Altria's transformation strategy [Item 15 - Exhibits, ¶1].

Altria's long-term strategy is organized around what management has termed the "Moving Beyond Smoking" vision, which focuses on transitioning adult smokers to potentially less harmful products. The company has invested significantly in smoke-free platforms including NJOY Ace (e-vapor), on! (oral nicotine pouches), and its heated tobacco product offerings, each of which faces distinct regulatory pathways to market and competitive dynamics. Management has previously communicated long-term goals for smoke-free product revenue growth and adult consumer adoption targets, though these forward-looking statements are subject to the cautionary note that actual results could differ materially due to the uncertainties inherent in evolving regulatory, competitive, and macroeconomic environments [Item 15 - Exhibits, ¶1]. The company's ability to maintain its dividend and investment-grade credit profile remains a foundational element of its financial strategy, with capital allocation priorities balancing robust shareholder returns — Altria has one of the highest dividend yields in the S&P 500 — with the investments required to execute the smoke-free transformation.

Conclusion

Altria Group, Inc. presents a dual narrative that captures both the challenges and opportunities facing one of America's most iconic consumer staples companies. On one hand, the company manages a deeply profitable but structurally declining cigarette franchise anchored by the Marlboro brand, generating substantial cash flows that support industry-leading shareholder returns through dividends and share repurchases. On the other hand, Altria is investing aggressively in a portfolio of smoke-free product platforms — including NJOY, on!, and heated tobacco — while maintaining strategic investments such as its significant stake in Anheuser-Busch InBev that provide portfolio diversification and exposure to adjacent consumer categories. The company's future will be determined by its ability to navigate an increasingly complex regulatory environment under the FDA, execute its smoke-free transition at a pace that offsets combustible volume declines, and maintain the financial discipline that has made it a mainstay of income-oriented portfolios. This 10-K/A amendment, by incorporating the ABI financial statements and related certifications, offers a window into Altria's broader strategic and financial framework — one defined by the disciplined management of legacy cash flows and the calculated pursuit of a transformed future [Item 15 - Exhibits, ¶1].